Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results

Phase III Data Could Lead To First Approval

Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.

Vitiligo on the hands. Shutterstock 1621981522
Incyte reported positive Phase III topline results for topical ruxolitinib in vitiligo • Source: Shutterstock

More from Dermatological

More from Therapy Areas